Long-acting formulations for the treatment of latent tuberculous infection

Opportunities and challenges

Susan Swindells, M. Siccardi, S. E. Barrett, D. B. Olsen, J. A. Grobler, Anthony T Podany, E. Nuermberger, P. Kim, C. E. Barry, A. Owen, D. Hazuda, C. Flexner

Research output: Contribution to journalReview article

8 Citations (Scopus)

Abstract

Long-acting/extended-release drug formulations have proved very successful in diverse areas of medicine, including contraception, psychiatry and, most recently, human immunodeficiency virus (HIV) disease. Though challenging, application of this technology to antituberculosis treatment could have substantial impact. The duration of treatment required for all forms of tuberculosis (TB) put existing regimens at risk of failure because of early discontinuations and treatment loss to follow-up. Long-acting injections, for example, administered every month, could improve patient adherence and treatment outcomes. We review the state of the science for potential long-acting formulations of existing tuberculosis drugs, and propose a target product profile for new formulations to treat latent tuberculous infection (LTBI). The physicochemical properties of some anti-tuberculosis drugs make them unsuitable for long-acting formulation, but there are promising candidates that have been identified through modeling and simulation, as well as other novel agents and formulations in preclinical testing. An efficacious long-acting treatment for LTBI, particularly for those co-infected with HIV, and if coupled with a biomarker to target those at highest risk for disease progression, would be an important tool to accelerate progress towards TB elimination.

Original languageEnglish (US)
Pages (from-to)125-132
Number of pages8
JournalInternational Journal of Tuberculosis and Lung Disease
Volume22
Issue number2
DOIs
StatePublished - Feb 1 2018

Fingerprint

Tuberculosis
Infection
HIV
Drug Compounding
Virus Diseases
Therapeutics
Patient Compliance
Contraception
Pharmaceutical Preparations
Psychiatry
Disease Progression
Biomarkers
Medicine
Technology
Injections

Keywords

  • Extended release
  • Long-acting
  • LTBI
  • Tuberculosis

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Infectious Diseases

Cite this

Long-acting formulations for the treatment of latent tuberculous infection : Opportunities and challenges. / Swindells, Susan; Siccardi, M.; Barrett, S. E.; Olsen, D. B.; Grobler, J. A.; Podany, Anthony T; Nuermberger, E.; Kim, P.; Barry, C. E.; Owen, A.; Hazuda, D.; Flexner, C.

In: International Journal of Tuberculosis and Lung Disease, Vol. 22, No. 2, 01.02.2018, p. 125-132.

Research output: Contribution to journalReview article

Swindells, S, Siccardi, M, Barrett, SE, Olsen, DB, Grobler, JA, Podany, AT, Nuermberger, E, Kim, P, Barry, CE, Owen, A, Hazuda, D & Flexner, C 2018, 'Long-acting formulations for the treatment of latent tuberculous infection: Opportunities and challenges', International Journal of Tuberculosis and Lung Disease, vol. 22, no. 2, pp. 125-132. https://doi.org/10.5588/ijtld.17.0486
Swindells, Susan ; Siccardi, M. ; Barrett, S. E. ; Olsen, D. B. ; Grobler, J. A. ; Podany, Anthony T ; Nuermberger, E. ; Kim, P. ; Barry, C. E. ; Owen, A. ; Hazuda, D. ; Flexner, C. / Long-acting formulations for the treatment of latent tuberculous infection : Opportunities and challenges. In: International Journal of Tuberculosis and Lung Disease. 2018 ; Vol. 22, No. 2. pp. 125-132.
@article{032f0354d4a24b2c889f9465476d1af0,
title = "Long-acting formulations for the treatment of latent tuberculous infection: Opportunities and challenges",
abstract = "Long-acting/extended-release drug formulations have proved very successful in diverse areas of medicine, including contraception, psychiatry and, most recently, human immunodeficiency virus (HIV) disease. Though challenging, application of this technology to antituberculosis treatment could have substantial impact. The duration of treatment required for all forms of tuberculosis (TB) put existing regimens at risk of failure because of early discontinuations and treatment loss to follow-up. Long-acting injections, for example, administered every month, could improve patient adherence and treatment outcomes. We review the state of the science for potential long-acting formulations of existing tuberculosis drugs, and propose a target product profile for new formulations to treat latent tuberculous infection (LTBI). The physicochemical properties of some anti-tuberculosis drugs make them unsuitable for long-acting formulation, but there are promising candidates that have been identified through modeling and simulation, as well as other novel agents and formulations in preclinical testing. An efficacious long-acting treatment for LTBI, particularly for those co-infected with HIV, and if coupled with a biomarker to target those at highest risk for disease progression, would be an important tool to accelerate progress towards TB elimination.",
keywords = "Extended release, Long-acting, LTBI, Tuberculosis",
author = "Susan Swindells and M. Siccardi and Barrett, {S. E.} and Olsen, {D. B.} and Grobler, {J. A.} and Podany, {Anthony T} and E. Nuermberger and P. Kim and Barry, {C. E.} and A. Owen and D. Hazuda and C. Flexner",
year = "2018",
month = "2",
day = "1",
doi = "10.5588/ijtld.17.0486",
language = "English (US)",
volume = "22",
pages = "125--132",
journal = "International Journal of Tuberculosis and Lung Disease",
issn = "1027-3719",
publisher = "International Union against Tubercul. and Lung Dis.",
number = "2",

}

TY - JOUR

T1 - Long-acting formulations for the treatment of latent tuberculous infection

T2 - Opportunities and challenges

AU - Swindells, Susan

AU - Siccardi, M.

AU - Barrett, S. E.

AU - Olsen, D. B.

AU - Grobler, J. A.

AU - Podany, Anthony T

AU - Nuermberger, E.

AU - Kim, P.

AU - Barry, C. E.

AU - Owen, A.

AU - Hazuda, D.

AU - Flexner, C.

PY - 2018/2/1

Y1 - 2018/2/1

N2 - Long-acting/extended-release drug formulations have proved very successful in diverse areas of medicine, including contraception, psychiatry and, most recently, human immunodeficiency virus (HIV) disease. Though challenging, application of this technology to antituberculosis treatment could have substantial impact. The duration of treatment required for all forms of tuberculosis (TB) put existing regimens at risk of failure because of early discontinuations and treatment loss to follow-up. Long-acting injections, for example, administered every month, could improve patient adherence and treatment outcomes. We review the state of the science for potential long-acting formulations of existing tuberculosis drugs, and propose a target product profile for new formulations to treat latent tuberculous infection (LTBI). The physicochemical properties of some anti-tuberculosis drugs make them unsuitable for long-acting formulation, but there are promising candidates that have been identified through modeling and simulation, as well as other novel agents and formulations in preclinical testing. An efficacious long-acting treatment for LTBI, particularly for those co-infected with HIV, and if coupled with a biomarker to target those at highest risk for disease progression, would be an important tool to accelerate progress towards TB elimination.

AB - Long-acting/extended-release drug formulations have proved very successful in diverse areas of medicine, including contraception, psychiatry and, most recently, human immunodeficiency virus (HIV) disease. Though challenging, application of this technology to antituberculosis treatment could have substantial impact. The duration of treatment required for all forms of tuberculosis (TB) put existing regimens at risk of failure because of early discontinuations and treatment loss to follow-up. Long-acting injections, for example, administered every month, could improve patient adherence and treatment outcomes. We review the state of the science for potential long-acting formulations of existing tuberculosis drugs, and propose a target product profile for new formulations to treat latent tuberculous infection (LTBI). The physicochemical properties of some anti-tuberculosis drugs make them unsuitable for long-acting formulation, but there are promising candidates that have been identified through modeling and simulation, as well as other novel agents and formulations in preclinical testing. An efficacious long-acting treatment for LTBI, particularly for those co-infected with HIV, and if coupled with a biomarker to target those at highest risk for disease progression, would be an important tool to accelerate progress towards TB elimination.

KW - Extended release

KW - Long-acting

KW - LTBI

KW - Tuberculosis

UR - http://www.scopus.com/inward/record.url?scp=85040766529&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85040766529&partnerID=8YFLogxK

U2 - 10.5588/ijtld.17.0486

DO - 10.5588/ijtld.17.0486

M3 - Review article

VL - 22

SP - 125

EP - 132

JO - International Journal of Tuberculosis and Lung Disease

JF - International Journal of Tuberculosis and Lung Disease

SN - 1027-3719

IS - 2

ER -